- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Neuromuscular Blocking Agent (NMBA) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Neuromuscular Blocking Agent (NMBA) size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Neuromuscular Blocking Agent (NMBA) market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Neuromuscular Blocking Agent (NMBA) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Depolarizing
Non-depolarizing
Market segment by Application can be divided into
Hospital
Clinic
Pharmacy
Others
The key market players for global Neuromuscular Blocking Agent (NMBA) market are listed below:
AbbVie
GlaxoSmithKline
Pfizer
Hengrui Pharmaceutical
Abbott Laboratories
Fresenius Kabi
Sandoz
Somerset Therapeutics
Guike Pharmaceutical
Shanghai Pharmaceuticals
Themis Medicare
Nanjing King-Friend
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Neuromuscular Blocking Agent (NMBA) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuromuscular Blocking Agent (NMBA), with price, sales, revenue and global market share of Neuromuscular Blocking Agent (NMBA) in 2018 and 2019.
Chapter 3, the Neuromuscular Blocking Agent (NMBA) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuromuscular Blocking Agent (NMBA) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Neuromuscular Blocking Agent (NMBA) market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Neuromuscular Blocking Agent (NMBA) sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Neuromuscular Blocking Agent (NMBA) Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuromuscular Blocking Agent (NMBA) Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Depolarizing
1.2.3 Non-depolarizing
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuromuscular Blocking Agent (NMBA) Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Others
1.4 Global Neuromuscular Blocking Agent (NMBA) Market Size & Forecast
1.4.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Value (2016-2026))
1.4.2 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume (2016-2026)
1.4.3 Global Neuromuscular Blocking Agent (NMBA) Price by Type (2016-2026) & (USD/MT)
1.5 Global Neuromuscular Blocking Agent (NMBA) Production Capacity Analysis
1.5.1 Global Neuromuscular Blocking Agent (NMBA) Total Production Capacity (2016-2026)
1.5.2 Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuromuscular Blocking Agent (NMBA) Market Drivers
1.6.2 Neuromuscular Blocking Agent (NMBA) Market Restraints
1.6.3 Neuromuscular Blocking Agent (NMBA) Trends Analysis
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Neuromuscular Blocking Agent (NMBA) Product and Services
2.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product and Services
2.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Neuromuscular Blocking Agent (NMBA) Product and Services
2.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Hengrui Pharmaceutical
2.4.1 Hengrui Pharmaceutical Details
2.4.2 Hengrui Pharmaceutical Major Business
2.4.3 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services
2.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Abbott Laboratories
2.5.1 Abbott Laboratories Details
2.5.2 Abbott Laboratories Major Business
2.5.3 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product and Services
2.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Fresenius Kabi
2.6.1 Fresenius Kabi Details
2.6.2 Fresenius Kabi Major Business
2.6.3 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product and Services
2.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Sandoz
2.7.1 Sandoz Details
2.7.2 Sandoz Major Business
2.7.3 Sandoz Neuromuscular Blocking Agent (NMBA) Product and Services
2.7.4 Sandoz Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Somerset Therapeutics
2.8.1 Somerset Therapeutics Details
2.8.2 Somerset Therapeutics Major Business
2.8.3 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product and Services
2.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Guike Pharmaceutical
2.9.1 Guike Pharmaceutical Details
2.9.2 Guike Pharmaceutical Major Business
2.9.3 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services
2.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Shanghai Pharmaceuticals
2.10.1 Shanghai Pharmaceuticals Details
2.10.2 Shanghai Pharmaceuticals Major Business
2.10.3 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product and Services
2.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 Themis Medicare
2.11.1 Themis Medicare Details
2.11.2 Themis Medicare Major Business
2.11.3 Themis Medicare Neuromuscular Blocking Agent (NMBA) Product and Services
2.11.4 Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 Nanjing King-Friend
2.12.1 Nanjing King-Friend Details
2.12.2 Nanjing King-Friend Major Business
2.12.3 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product and Services
2.12.4 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturer
3.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Neuromuscular Blocking Agent (NMBA)
3.4 Market Concentration Rate
3.4.1 Top 3 Neuromuscular Blocking Agent (NMBA) Manufacturer Market Share
3.4.2 Top 6 Neuromuscular Blocking Agent (NMBA) Manufacturer Market Share
3.5 Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Neuromuscular Blocking Agent (NMBA) Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Region
4.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Region (2016-2026)
4.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2016-2026)
4.2 North America Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
4.3 Europe Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
4.4 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
4.5 South America Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
4.6 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Type (2016-2026)
5.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2016-2026)
5.3 Global Neuromuscular Blocking Agent (NMBA) Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Application (2016-2026)
6.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2016-2026)
6.3 Global Neuromuscular Blocking Agent (NMBA) Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
7.2 North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
7.3 North America Neuromuscular Blocking Agent (NMBA) Market Size by Country
7.3.1 North America Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2016-2026)
7.3.2 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
8.2 Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
8.3 Europe Neuromuscular Blocking Agent (NMBA) Market Size by Country
8.3.1 Europe Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2016-2026)
8.3.2 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
9.2 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
9.3 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market Size by Region
9.3.1 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
10.2 South America Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
10.3 South America Neuromuscular Blocking Agent (NMBA) Market Size by Country
10.3.1 South America Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2016-2026)
10.3.2 South America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
11.2 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
11.3 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Market Size by Country
11.3.1 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Neuromuscular Blocking Agent (NMBA) Typical Distributors
12.3 Neuromuscular Blocking Agent (NMBA) Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type, (USD Million), 2021-2026
Table 2. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application, (USD Million), 2021-2026
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Neuromuscular Blocking Agent (NMBA) Product and Services
Table 6. AbbVie Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline Major Business
Table 9. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product and Services
Table 10. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Pfizer Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Major Business
Table 13. Pfizer Neuromuscular Blocking Agent (NMBA) Product and Services
Table 14. Pfizer Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Hengrui Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 16. Hengrui Pharmaceutical Major Business
Table 17. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services
Table 18. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 20. Abbott Laboratories Major Business
Table 21. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product and Services
Table 22. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 24. Fresenius Kabi Major Business
Table 25. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product and Services
Table 26. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Sandoz Basic Information, Manufacturing Base and Competitors
Table 28. Sandoz Major Business
Table 29. Sandoz Neuromuscular Blocking Agent (NMBA) Product and Services
Table 30. Sandoz Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Somerset Therapeutics Basic Information, Manufacturing Base and Competitors
Table 32. Somerset Therapeutics Major Business
Table 33. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product and Services
Table 34. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Guike Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Guike Pharmaceutical Major Business
Table 37. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services
Table 38. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Shanghai Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 40. Shanghai Pharmaceuticals Major Business
Table 41. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product and Services
Table 42. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Themis Medicare Basic Information, Manufacturing Base and Competitors
Table 44. Themis Medicare Major Business
Table 45. Themis Medicare Neuromuscular Blocking Agent (NMBA) Product and Services
Table 46. Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Nanjing King-Friend Basic Information, Manufacturing Base and Competitors
Table 48. Nanjing King-Friend Major Business
Table 49. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product and Services
Table 50. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Global Neuromuscular Blocking Agent (NMBA) Sales by Manufacturer (2019-2021e) & (MT)
Table 52. Global Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 53. Market Position of Manufacturers in Neuromuscular Blocking Agent (NMBA), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 54. Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Company, (MT): 2020 VS 2021
Table 55. Head Office and Neuromuscular Blocking Agent (NMBA) Production Site of Key Manufacturer
Table 56. Neuromuscular Blocking Agent (NMBA) New Entrant and Capacity Expansion Plans
Table 57. Neuromuscular Blocking Agent (NMBA) Mergers & Acquisitions in the Past Five Years
Table 58. Global Neuromuscular Blocking Agent (NMBA) Sales by Region (2016-2021e) & (MT)
Table 59. Global Neuromuscular Blocking Agent (NMBA) Sales by Region (2021-2026) & (MT)
Table 60. Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2016-2021e) & (USD Million)
Table 61. Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2021-2026) & (USD Million)
Table 62. Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 63. Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 64. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2016-2021e) & (USD Million)
Table 65. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2021-2026) & (USD Million)
Table 66. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2016-2021e) & (USD/MT)
Table 67. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2021-2026) & (USD/MT)
Table 68. Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 69. Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 70. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2016-2021e) & (USD Million)
Table 71. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2021-2026) & (USD Million)
Table 72. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2016-2021e) & (USD/MT)
Table 73. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2021-2026) & (USD/MT)
Table 74. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2016-2021e) & (MT)
Table 75. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2021-2026) & (MT)
Table 76. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2021e) & (USD Million)
Table 77. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2021-2026) & (USD Million)
Table 78. North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 79. North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 80. North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 81. North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 82. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2016-2021e) & (MT)
Table 83. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2021-2026) & (MT)
Table 84. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2021e) & (USD Million)
Table 85. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2021-2026) & (USD Million)
Table 86. Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 87. Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 88. Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 89. Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 90. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2016-2021e) & (MT)
Table 91. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2021-2026) & (MT)
Table 92. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2016-2021e) & (USD Million)
Table 93. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2021-2026) & (USD Million)
Table 94. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 95. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 96. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 97. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 98. South America Neuromuscular Blocking Agent (NMBA) Sales by Country (2016-2021e) & (MT)
Table 99. South America Neuromuscular Blocking Agent (NMBA) Sales by Country (2021-2026) & (MT)
Table 100. South America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2021e) & (USD Million)
Table 101. South America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2021-2026) & (USD Million)
Table 102. South America Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 103. South America Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 104. South America Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 105. South America Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 106. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2016-2021e) & (MT)
Table 107. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2021-2026) & (MT)
Table 108. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2021e) & (USD Million)
Table 109. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2021-2026) & (USD Million)
Table 110. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 111. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 112. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 113. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 114. Direct Channel Pros & Cons
Table 115. Indirect Channel Pros & Cons
Table 116. Neuromuscular Blocking Agent (NMBA) Typical Distributors
Table 117. Neuromuscular Blocking Agent (NMBA) Typical Customers
List of Figures
Figure 1. Neuromuscular Blocking Agent (NMBA) Picture
Figure 2. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type in 2020
Figure 3. Depolarizing
Figure 4. Non-depolarizing
Figure 5. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application in 2020
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Pharmacy
Figure 9. Others
Figure 10. Global Neuromuscular Blocking Agent (NMBA) Market Size, (USD Million) & (MT): 2020 VS 2021 VS 2026
Figure 11. Global Neuromuscular Blocking Agent (NMBA) Market Size and Forecast (2016-2026) & (USD Million)
Figure 12. Global Neuromuscular Blocking Agent (NMBA) Sales (2016-2026) & (MT)
Figure 13. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2016-2026) & (USD/MT)
Figure 14. Global Neuromuscular Blocking Agent (NMBA) Production Capacity (2016-2026) & (MT)
Figure 15. Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Geographic Region: 2020 VS 2021
Figure 16. Neuromuscular Blocking Agent (NMBA) Market Drivers
Figure 17. Neuromuscular Blocking Agent (NMBA) Market Restraints
Figure 18. Neuromuscular Blocking Agent (NMBA) Market Trends
Figure 19. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturer in 2020
Figure 20. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Manufacturer in 2020
Figure 21. Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 22. Top 3 Neuromuscular Blocking Agent (NMBA) Manufacturer (Revenue) Market Share in 2020
Figure 23. Top 6 Neuromuscular Blocking Agent (NMBA) Manufacturer (Revenue) Market Share in 2020
Figure 24. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2016-2026)
Figure 25. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2016-2026)
Figure 26. North America Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 27. Europe Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 28. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 29. South America Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 30. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 31. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 32. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2016-2026)
Figure 33. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2016-2026) & (USD/MT)
Figure 34. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 35. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2016-2026)
Figure 36. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2016-2026) & (USD/MT)
Figure 37. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 38. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 39. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2016-2026)
Figure 40. North America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2016-2026)
Figure 41. United States Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Canada Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Mexico Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 45. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 46. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2016-2026)
Figure 47. Europe Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2016-2026)
Figure 48. Germany Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. France Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. United Kingdom Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Russia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Italy Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2016-2026)
Figure 54. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 55. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2016-2026)
Figure 57. China Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Korea Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 64. South America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 65. South America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2016-2026)
Figure 66. South America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 70. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 71. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Egypt Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. South Africa Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Sales Channel: Direct Channel vs Indirect Channel
Figure 78. Methodology
Figure 79. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
